Skip to main content
. 2024 Apr 10;67(8):6064–6080. doi: 10.1021/acs.jmedchem.4c00133

Table 5. Characterization of Cellular Activity, Permeability, Efflux, and Metabolic Stability of Compounds 28 and 29.

graphic file with name jm4c00133_0025.jpg

graphic file with name jm4c00133_0026.jpg

a

Inhibition of PRMT5 determined by an SDMA in-cell western assay in the HAP1 MTAP-isogenic cell line pair following compound treatment for 24 h.

b

Viability growth inhibition assessed after 7 days of compound treatment using a CellTiter-Glo luminescence-based assay in the same HAP1 MTAP-isogenic cells.

c

MDCKII-WT A–B (10–6 cm/s).

d

MDCKII-Mdr1 cells (A–B)/(B–A).

e

Human liver microsomes, Clint, μL/min/mg.